MRSN - NASDAQ

Mersana Therapeutics, Inc.

MRSN·NASDAQ

$29.08

+0.0000%

HealthcareBiotechnology

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$145.36M

EPS-14.1200

P/E Ratio-2.53

Earnings Date03/02/2026

144.66M

Assets

-36%

3Y-30.0%

5Y+35.0%

10Y+904.0%

154.17M

Total Liabilities

-18%

3Y+83.0%

5Y+428.0%

10Y+170.0%

-9.51M

Total Equity

-126%

3Y-108.0%

5Y-112.0%

10Y-78.0%

Mersana Therapeutics, Inc. Funding & Solvency Profile

MRSN · NASDAQ

Current Assets

Cash & Cash Equivalents107.75M

Net Receivables0.00

Inventory0.00

Other Current Assets2.28M

Total Current Assets137 M

Non-Current Assets

Property, Plant & Equipment6.78M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets978.00K

Total Non-Current Assets8 M

Total Assets

144.66M

Financial Health Analysis

Current Ratio

2.19x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

74 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Mersana Therapeutics, Inc. Balance Sheet

MRSN • NASDAQ

Mersana Therapeutics, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	107.8M	174.6M	128.9M	177.9M	255.1M	62.4M	59.6M	26.6M	100.3M	11.5M
Short-Term Investments	26.9M	34.5M	151.8M	0.0	0.0	37.4M	10.5M	88.1M	0.0	0.0
Cash & Short-Term Investments	134.6M	209.1M	280.7M	177.9M	255.1M	99.8M	70.1M	114.7M	100.3M	11.5M
Net Receivables	0.0	0.0	30M	0.0	0.0	0.0	459K	784K	1.1M	640K
Accounts Receivables	0.0	0.0	30M	0.0	0.0	0.0	459K	784K	1.1M	640K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	-4.2M	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	3.5M	0.0	3.7M	2M	825K	580K
Other Current Assets	2.3M	5M	8.5M	11M	0.0	1.5M	3.7M	2M	0.0	0.0
Total Current Assets	136.9M	214.1M	319.2M	188.9M	258.6M	101.3M	70.1M	117.5M	102.2M	12.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	6.8M	11.5M	14.5M	14.9M	12.7M	4.8M	2.7M	2.3M	2.5M	1.3M
Long-Term Investments	0.0	0.0	0.0	478K	321.0	321K	371K	10.5M	321K	0.0
Other Non-Current Assets	978K	478K	661K	1.9M	2.2M	1.1M	5.3M	371K	110K	371K
Total Non-Current Assets	7.8M	12M	15.1M	17.2M	14.8M	6.2M	8.4M	13.2M	2.9M	1.7M
Total Assets	144.7M	226.1M	334.3M	206.1M	273.4M	107.5M	78.5M	130.7M	105.1M	14.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.3M	7.3M	14M	12.3M	8.3M	7.3M	10.7M	3.1M	2.1M	2M
Accounts Payable	4.3M	7.3M	14M	12.3M	8.3M	7.3M	10.7M	3.1M	2.1M	2M
Accrued Expenses	7.3M	8.8M	43.2M	7.3M	5.4M	4M	3M	3M	2.3M	1.7M
Short Term Debt	12.5M	2.1M	0.0	0.0	93K	667K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	3.9M	3.4M	2.8M	2.3M	1.4M	2.2M	0.0	0.0	0.0	0.0
Deferred Revenue	22.2M	28.1M	30.6M	3.9M	4M	4.8M	46.2M	21.6M	22.7M	7.1M
Other Current Liabilities	12.3M	13.9M	990K	21.6M	10.8M	5M	9.5M	4.1M	1.3M	0.0
Total Current Liabilities	62.5M	63.6M	91.5M	47.5M	30M	24.1M	69.4M	31.9M	28.4M	10.7M
NON-CURRENT LIABILITIES
Long Term Debt	11M	23.1M	24.9M	24.6M	5M	4.2M	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	79.5M	97.2M	117M	0.0	0.0	0.0	0.0	28.8M	37.6M	10.1M
Other Non-Current Liabilities	8K	1K	203K	974K	174K	275K	282K	67K	94.7M	36.3M
Total Non-Current Liabilities	91.7M	125.5M	150.8M	36.8M	15.3M	5.2M	282K	28.8M	132.3M	46.4M
Capital Lease Obligations	5.1M	8.6M	11.4M	13.6M	11.6M	2.9M	0.0	0.0	0.0	0.0
Total Liabilities	154.2M	189.2M	242.3M	84.4M	45.3M	29.2M	69.7M	60.7M	160.7M	57.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	130.7M	94.5M	36.3M
Common Stock	12K	12K	11K	7K	7K	5K	3K	3K	1K	1K
Additional Paid-In Capital	886M	863.2M	746.9M	572.2M	508.5M	270.7M	173M	168M	3.6M	2.8M
Retained Earnings	-895.6M	-826.4M	-654.7M	-450.5M	-280.4M	-192.4M	-164.2M	-97.9M	-59.2M	-45.5M
Accumulated Other Comprehensive Income/Loss	10K	11K	-152K	0.0	0.0	25K	-8K	-149K	-4.2M	-3.6M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2M	3.6M
Total Stockholders' Equity	-9.5M	36.9M	92.1M	121.7M	228.1M	78.3M	8.8M	70M	-55.6M	-42.7M
Total Equity	-9.5M	36.9M	92.1M	121.7M	228.1M	78.3M	8.8M	70M	-55.6M	-42.7M
SUMMARY
Total Liabilities & Equity	144.7M	226.1M	334.3M	206.1M	273.4M	107.5M	78.5M	130.7M	105.1M	14.4M
Total Investments	26.9M	34.5M	151.8M	478K	321.0	37.8M	10.5M	98.6M	321K	0.0
Total Debt	28.6M	33.8M	36.3M	38.2M	16.7M	7.8M	0.0	0.0	0.0	0.0
Net Debt	-79.2M	-140.7M	-92.6M	-139.8M	-238.4M	-54.6M	-59.6M	-26.6M	-100.3M	-11.5M
Shares Outstanding	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728	4,990,728

SEC Filings

MRSN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 06, 2026	January 05, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 05, 2025	September 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 13, 2025	August 13, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 13, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 24, 2025	July 24, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 03, 2025	July 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 13, 2025	June 12, 2025	2025	View Filing

Showing 1 to 10 of 162 filings

Related Guides

Blog Categories

Continue your MRSN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.